• Amitriptyline and Ondansetron for Irritable Bowel Syndrome: Efficacy data from the ground breaking studies

  • Jun 21 2024
  • Length: 54 mins
  • Podcast

Amitriptyline and Ondansetron for Irritable Bowel Syndrome: Efficacy data from the ground breaking studies

  • Summary

  • On this special episode of Tuesday Night IBS, we talk with the co-principal investigator, Alex Ford, MD, from Leeds University in the UK, about the ATLANTIS trial of Amitriptyline for irritable bowel syndrome (IBS) in primary care, which was funded by the Health Technology Assessment program of the National Institute for Health and Care Research and the TRITON trial using Ondansetron to manage irritable bowel syndrome with diarrhea.

    Dr. Alex Ford is a Professor and Honorary consultant gastroenterologist at St. James’s University Hospital, Leeds, UK. His main interest is in the epidemiology, diagnosis, and treatment of disorders of gut-brain interaction, such as irritable bowel syndrome and functional dyspepsia. He is an Associate Editor for Alimentary Pharmacology & Therapeutics. He has published over 450 peer-reviewed articles, including original scientific papers in The Lancet, JAMA, BMJ, Gastroenterology, Gut, Archives of Internal Medicine, and The American Journal of Gastroenterology.

    Show More Show Less

What listeners say about Amitriptyline and Ondansetron for Irritable Bowel Syndrome: Efficacy data from the ground breaking studies

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.